AR090312A1 - HETEROCICLICAL COMPOUND - Google Patents

HETEROCICLICAL COMPOUND

Info

Publication number
AR090312A1
AR090312A1 ARP130100792A ARP130100792A AR090312A1 AR 090312 A1 AR090312 A1 AR 090312A1 AR P130100792 A ARP130100792 A AR P130100792A AR P130100792 A ARP130100792 A AR P130100792A AR 090312 A1 AR090312 A1 AR 090312A1
Authority
AR
Argentina
Prior art keywords
group
lower alkyl
alkyl group
heterocyclic
aromatic
Prior art date
Application number
ARP130100792A
Other languages
Spanish (es)
Inventor
Shinohara Tomoichi
Sasaki Hirofumi
Tai Kuninori
Ito Nobuaki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR090312A1 publication Critical patent/AR090312A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Útiles en tratamiento de enfermedades del SNC como la depresión. Reivindicación 1: Un medicamento que comprende un compuesto heterocíclico representado por la fórmula general (1) o una sal del mismo, caracterizado porque m, l, y n respectivamente representan un entero de 1 ó 2; X representa -O- ó -CH₂-; R¹ representa hidrógeno, un grupo alquilo inferior, un grupo hidroxi-alquilo inferior, un grupo protector, o un grupo tri-alquilsililoxi inferior-alquilo inferior; R² y R³, los cuales son iguales o diferentes, cada uno representa independientemente hidrógeno o un grupo alquilo inferior; o R² y R³ se unen para formar un grupo cicloalquilo C₃₋₈; y R⁴ representa un grupo aromático o un grupo heterocíclico, donde el grupo aromático o heterocíclico puede tener uno o más sustituyentes arbitrarios.Useful in the treatment of CNS diseases such as depression. Claim 1: A medicament comprising a heterocyclic compound represented by the general formula (1) or a salt thereof, characterized in that m, l, and n respectively represent an integer of 1 or 2; X represents -O- or -CH₂-; R¹ represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a lower tri-alkylsilyloxy-lower alkyl group; R² and R³, which are the same or different, each independently represents hydrogen or a lower alkyl group; or R² and R³ join to form a C₃₋₈ cycloalkyl group; and R⁴ represents an aromatic group or a heterocyclic group, where the aromatic or heterocyclic group may have one or more arbitrary substituents.

ARP130100792A 2012-03-12 2013-03-12 HETEROCICLICAL COMPOUND AR090312A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012054467 2012-03-12

Publications (1)

Publication Number Publication Date
AR090312A1 true AR090312A1 (en) 2014-11-05

Family

ID=48048149

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100792A AR090312A1 (en) 2012-03-12 2013-03-12 HETEROCICLICAL COMPOUND

Country Status (4)

Country Link
JP (1) JP6415982B2 (en)
AR (1) AR090312A1 (en)
TW (1) TW201348215A (en)
WO (1) WO2013137479A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015196086A1 (en) * 2014-06-20 2015-12-23 The University of Montana, Missoula, MT NOVEL INHIBITORS OF SYSTEM Xc(-)
CA3223576A1 (en) * 2021-07-13 2023-01-19 Otsuka Pharmaceutical Co., Ltd. Hydrogenated quinoxalines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4210941A1 (en) * 1992-04-02 1993-10-07 Bayer Ag New 9-fluoro-7.oxo-7H-pyrido [1,2,3-d, e] [1,4] benzoxacin-6-carboxylic acids and esters
ATE273970T1 (en) * 1998-04-16 2004-09-15 Pfizer Prod Inc N-ACYL AND N-AROYL ARALKYLAMIDE
IT1312310B1 (en) * 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma USE OF SELECTIVE 1B ADRENERGIC RECEPTOR ANTAGONISTS TO IMPROVE SEXUAL DYSFUNCTION
JP2007537151A (en) * 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク Combination of γ-aminobutyric acid modulator and 5-HT1B receptor antagonist
MX2009001494A (en) * 2006-08-07 2009-04-23 Albany Molecular Res Inc 2-aminobenzoxazole carboxamides as 5ht3 modulators.
JP2012528871A (en) * 2009-06-03 2012-11-15 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
WO2011068171A1 (en) * 2009-12-03 2011-06-09 第一三共株式会社 Bicyclic nitrogen-containing saturated heterocyclic derivatives
BR112013005823B8 (en) * 2010-09-13 2022-11-22 Otsuka Pharma Co Ltd HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREFNEPHRINE OR DOPAMINE

Also Published As

Publication number Publication date
JP6415982B2 (en) 2018-10-31
JP2015513521A (en) 2015-05-14
WO2013137479A1 (en) 2013-09-19
TW201348215A (en) 2013-12-01

Similar Documents

Publication Publication Date Title
CR20160564A (en) CYCLIC DINUCLEOTIDES AS STING MODULATORS
BR112015022804A2 (en) new octahidro-pyrrol [3,4-c] -pyrrol derivatives and their analogues as autotaxin inhibitors
CO2018000589A2 (en) Oxiesterols and pharmaceutical compositions containing them
CR20140525A (en) N-alkyltriazole compounds as LPAR antagonists
UY35237A (en) COMPOSITIONS THAT INCLUDE A TRIAZOL COMPOUND
UY35238A (en) COMPOSITIONS THAT INCLUDE A TRIAZOL COMPOUND
CO7350620A2 (en) New pyridine derivatives
AR101815A1 (en) COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
IN2014MN02331A (en)
IN2014MN02244A (en)
CR20150268A (en) NEW COMPOUNDS
IN2014MN02211A (en)
DOP2017000034A (en) IMIDAZOPIRIDAZINE COMPOUNDS
CL2019001041A1 (en) Therapeutic compounds and methods to use them.
DOP2014000178A (en) NEW BENCIL SULFONAMIDE DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS
AR095349A1 (en) COMPOUND AND PHARMACEUTICALLY ACCEPTABLE COMPOSITION, USEFUL TO TREAT DISEASE OR DISORDER SUCH AS HUNTINGTON'S DISEASE OR OTHER NEURODEGENERATIVE PATHOLOGY
UY35997A (en) ISOQUINOLEINE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CL2016001623A1 (en) Benzamide and nicotinamide compounds and methods for using them.
NI201600016A (en) NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTINUE THEM.
MX2016017305A (en) Herbicidally active arylcarboxylic acid amides.
CO2019005165A2 (en) Pyridone compound as c-met inhibitor
CR20150396A (en) HERBICIDE COMPOSITIONS THAT INCLUDE A CORNEXISTIN
NI201600163A (en) DIHETERO CYCLE DERIVATIVES LINKED TO CYCLOALKYL
CR20180298A (en) NEW DERIVATIVES OF PHENYL
AR082962A1 (en) DERIVATIVES OF QUINOXALINE AND PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure